Ligand Pharmaceuticals Cash Flow Statement

Financials in millions CAD. Fiscal year is April - March.

Millions CAD. Fiscal year is Apr - Mar.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2016 - 2020
Period Ending	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021	2016 - 2020
Net Income	-3.31	-6.64	-5.75	-4.69	-2.46	Upgrade
Depreciation & Amortization	1.04	0.75	1.08	0.48	0.16	Upgrade
Loss (Gain) From Sale of Investments	0.06	0.55	0.07	-	-	Upgrade
Stock-Based Compensation	0.13	1.79	2.19	0.63	0.99	Upgrade
Other Operating Activities	-0.16	-0.77	-1.02	-0.2	-	Upgrade
Change in Accounts Receivable	0.28	0.67	-0.33	-0.65	-0.12	Upgrade
Change in Accounts Payable	0.28	-0.33	0.36	-0.02	0.19	Upgrade
Change in Other Net Operating Assets	-0.11	-0.13	0.35	-0.05	0.04	Upgrade
Operating Cash Flow	-1.79	-4.11	-3.06	-4.5	-1.19	Upgrade
Capital Expenditures	-	-0.05	-0.51	-0.68	-0.22	Upgrade
Sale of Property, Plant & Equipment	-	-	0.72	-	-	Upgrade
Investing Cash Flow	-	-0.05	0.21	-0.68	-0.22	Upgrade
Issuance of Common Stock	1.1	2.32	6.62	3.21	3.51	Upgrade
Other Financing Activities	-0.07	-0.12	-0.22	-0.08	-0.16	Upgrade
Financing Cash Flow	1.03	2.2	6.4	3.13	3.35	Upgrade
Net Cash Flow	-0.75	-1.96	3.55	-2.05	1.94	Upgrade
Free Cash Flow	-1.79	-4.16	-3.57	-5.18	-1.41	Upgrade
Free Cash Flow Per Share	-0.03	-0.09	-0.14	-0.31	-0.15	Upgrade
Levered Free Cash Flow	-0.11	-3.22	2	-2.45	0.06	Upgrade
Unlevered Free Cash Flow	-0.11	-3.22	2	-2.45	0.06	Upgrade

Updated Mar 3, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.